ciltacabtagene autoleucel
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
FDA Wants Expert Input on Benefits, Risks of CAR T Therapy in Earlier-Line Multiple Myeloma
Ahead of an advisory committee meeting Friday, the agency has noted concerns about the risk of early death seen with BMS's Abecma and Janssen's Carvykti in trials.
J&J Oncology Revenues Jump 12 Percent in Q3
The firm touted sales gains for Carvykti and highlighted regulatory updates for Akeega, Balversa, and Rybrevant in Q3.
J&J Highlights Forthcoming Precision Rx Approvals, Indication Expansions in Multiple Myeloma
Premium
During a call to discuss Q2 earnings, J&J CEO Joaquin Duato discussed the company's aspirations to develop a treatment for every line of therapy for multiple myeloma patients.